Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06273340 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Experimental intervention: PF-06273340 or placebo | EXPERIMENTAL | Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated. |
| Cohort 2: Experimental intervention: PF-06273340 or placebo | EXPERIMENTAL | Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated. |
| Name | Type | Description |
|---|---|---|
| PF-06273340 or Placebo | DRUG | PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution. |
Inclusion Criteria: * Healthy male subjects or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * An informed consent document signed and dated by the subject * Su...
PF-06273340 is an investigational small molecule drug being developed by Pfizer, Inc. for the treatment of pain. It has been studied in a Phase 1 first-in-human clinical trial in healthy volunteers. It is not an approved medicine and remains in early clinical development.
PF-06273340 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 first-in-human study of the compound in healthy volunteers.
PF-06273340 is in Phase 1 clinical development. Its only recorded trial, NCT01601834, was a Phase 1 first-in-human study that has been completed. The drug is investigational and has not been approved for any indication.
PF-06273340 has been evaluated in one clinical trial, NCT01601834, titled A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340. The Phase 1 study enrolled 20 healthy adult volunteers in Belgium and is completed.
PF-06273340 is being studied for the treatment of pain. Its single completed Phase 1 trial listed pain as the condition under study, and it was tested in healthy volunteers rather than patients. No approved use exists for this investigational compound.
The Phase 1 trial NCT01601834 was a randomized, double-blind, controlled first-in-human study of single oral doses of PF-06273340. It enrolled 20 healthy volunteers of all sexes, aged 18 years and older, in Belgium, and assessed safety, toleration, and the time course of plasma concentration.